샘플 요청 목록

 카트 문의
시장보고서
상품코드
1655531

항생제 시장

Antibiotics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 266 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 항생제 시장은 2030년까지 503억 달러에 달할 전망

2024년에 419억 달러로 추정되는 세계의 항생제 시장은 2024-2030년에 CAGR 3.1%로 성장하며, 2030년에는 503억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 페니실린은 CAGR 3.3%를 기록하며, 분석 기간 종료시에는 157억 달러에 달할 것으로 예상됩니다. 세팔로스포린 부문의 성장률은 분석 기간 중 CAGR 3.8%로 추정됩니다.

미국 시장은 112억 달러로 추정, 중국은 CAGR 4.9%로 성장 예측

미국의 항생제 시장은 2024년에 112억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 102억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 4.9%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.0%와 2.5%로 예측됩니다. 유럽에서는 독일이 CAGR 2.5%로 성장할 것으로 예측됩니다.

세계의 항생제 시장 - 주요 동향과 촉진요인 정리

항생제: 현대 의학의 초석

항생제의 발견과 개발은 의학에 혁명을 가져왔고, 세균성 감염의 치료법을 변화시켰으며 수많은 생명을 구했습니다. 알렉산더 플레밍(Alexander Fleming)이 1896년에 발견한 페니실린은 최초의 진정한 항생제이자 치료의 새로운 시대를 열었습니다. 항생제가 등장하기 전에는 사소한 감염이 치명적인 경우가 많았고, 세균성 질환을 치료할 수 있는 선택지가 제한적이었습니다. 항생제의 도입은 폐렴, 결핵, 패혈증 등 다양한 감염 질환에 효과적인 치료법을 제공함으로써 사망률을 크게 낮추었습니다. 수년간 세팔로스포린, 테트라사이클린, 마크로리드와 같은 새로운 항생제 계열이 개발되면서 임상의가 사용할 수 있는 무기가 확대되어 다양한 세균 감염을 더 높은 특이성과 효과로 치료할 수 있게 되었습니다. 이 혁명은 개인의 건강 상태를 개선했을 뿐만 아니라 수술과 만성질환 관리의 발전을 촉진했습니다.

항생제의 유형과 그 기전은 무엇인가?

항생제는 화학 구조와 작용기전에 따라 몇 가지 범주로 나뉩니다. 페니실린과 세팔로스포린을 포함한 β-락탐계 항균제는 박테리아의 세포벽 합성을 파괴하여 세포 용해와 사멸을 유도합니다. 테트라사이클린계 항균제는 세균의 리보솜에 결합하여 단백질 합성을 억제하여 필수 단백질의 생성을 막습니다. 에리스로마이신과 같은 마크로리드계 항균제도 박테리아의 리보솜을 표적으로 삼지만, 다른 메커니즘으로 작용하므로 다른 스펙트럼의 박테리아에 효과적입니다. 아미노글리코사이드계 항균제도 마찬가지로 단백질 합성을 억제하지만, 특히 호기성 그람음성균에 효과적입니다. 시프로플록사신과 같은 플루오로퀴놀론계 항균제는 박테리아의 DNA 자イレ?ス와 토포이소머라제 IV를 표적으로 하여 DNA 복제를 억제합니다. 각 항생제 계열은 고유한 장점을 가지고 있으며, 특정 유형의 세균 감염을 표적으로 삼기 때문에 보다 맞춤화되고 효과적인 치료를 가능하게 합니다.

항생제 내성에는 어떤 문제가 있는가?

항생제 내성은 현대 의학이 직면한 가장 심각한 문제 중 하나입니다. 인간의 의료와 농업에서 항생제의 남용과 오용은 항생제 내성 박테리아의 개발을 가속화하고 있습니다. 박테리아는 항생제에 노출되면 약물을 비활성화하는 효소를 생산하거나, 약물의 표적 부위를 변경하거나, 약물을 세포 밖으로 내보내는 등 생존을 위한 메커니즘을 진화시킵니다. 내성 감염은 치료가 어렵고, 더 강력한 항생제가 필요하며, 치료 기간이 길어지고, 경우에 따라서는 사망률도 증가합니다. 메티실린 내성 황색포도상구균(MRSA)과 카바페넴 내성 장내세균(CRE)과 같은 다제내성균의 확산은 이 문제의 시급성을 강조하고 있습니다. 항생제 내성 퇴치를 위한 노력에는 새로운 항생제 개발, 기존 항생제 사용을 최적화하기 위한 항생제 스튜어드십 프로그램 시행, 항생제 오남용을 줄이고 대체 치료법 연구를 촉진하기 위한 전 세계적인 노력 등이 포함됩니다.

항생제 시장의 성장을 가속하는 요인은 무엇인가?

항생제 시장의 성장은 여러 가지 요인에 의해 주도되고 있습니다. 특히 인구 밀도가 높고 의료 접근성이 제한된 개발 도상국에서 세균성 감염증 증가는 중요한 촉진제입니다. 진단 기술의 발전으로 세균성 병원균의 검출 및 식별이 개선되어 항생제 치료를 보다 효과적으로 수행할 수 있게 되었습니다. 여러 항생제에 내성이 있는 병원내 감염이 증가함에 따라 보다 새롭고 효과적인 치료법의 개발과 사용이 필요하게 되었습니다. 또한 현재 진행 중인 연구개발은 기존 내성 문제를 극복하기 위해 독자적인 작용기전을 가진 새로운 항생제 발견에 초점을 맞추었습니다. 정부 및 의료기관의 규제 지원과 자금 지원도 새로운 항생제의 연구, 승인 및 상용화를 촉진하여 항생제 시장을 강화하고 있습니다. 또한 신흥 국가의 의료 인프라 확대와 의료비 증가는 항생제 접근성 및 수요 증가에 기여하며 시장 성장의 원동력이 되고 있습니다.

부문

약물 유형(페니실린, 세팔로스포린, 마크로리드, 플루오로퀴놀론, 테트라사이클린, 약물 유형별) ; & 투여 경로(비경구, 경구, 기타 투여 경로)

조사 대상 기업의 예(주목 합계 209사)

  • Abbott Laboratories, Inc.
  • Allergan PLC
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi
  • Shionogi, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.03.04

Global Antibiotics Market to Reach US$50.3 Billion by 2030

The global market for Antibiotics estimated at US$41.9 Billion in the year 2024, is expected to reach US$50.3 Billion by 2030, growing at a CAGR of 3.1% over the analysis period 2024-2030. Penicillin, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$15.7 Billion by the end of the analysis period. Growth in the Cephalosporin segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.2 Billion While China is Forecast to Grow at 4.9% CAGR

The Antibiotics market in the U.S. is estimated at US$11.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.2 Billion by the year 2030 trailing a CAGR of 4.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Antibiotics Market - Key Trends and Drivers Summarized

Antibiotics: The Cornerstone of Modern Medicine

The discovery and development of antibiotics revolutionized medicine, transforming the treatment of bacterial infections and saving countless lives. Penicillin, discovered by Alexander Fleming in 1928, was the first true antibiotic, marking the beginning of a new era in medical treatment. Before antibiotics, minor infections often turned deadly, and there were limited options for treating bacterial diseases. The introduction of antibiotics provided effective treatments for a wide range of infections, including pneumonia, tuberculosis, and sepsis, dramatically reducing mortality rates. Over the years, the development of new classes of antibiotics, such as cephalosporins, tetracyclines, and macrolides, expanded the arsenal available to clinicians, enabling the treatment of various bacterial infections with increasing specificity and effectiveness. This revolution not only improved individual health outcomes but also facilitated advancements in surgical procedures and the management of chronic diseases.

What Are the Different Classes of Antibiotics and Their Mechanisms?

Antibiotics are classified into several categories based on their chemical structure and mechanism of action. Beta-lactams, including penicillins and cephalosporins, disrupt bacterial cell wall synthesis, leading to cell lysis and death. Tetracyclines inhibit protein synthesis by binding to the bacterial ribosome, preventing the production of essential proteins. Macrolides, such as erythromycin, also target bacterial ribosomes but do so by a different mechanism, which makes them effective against a different spectrum of bacteria. Aminoglycosides interfere with protein synthesis as well but are particularly effective against aerobic gram-negative bacteria. Fluoroquinolones, like ciprofloxacin, inhibit DNA replication by targeting bacterial DNA gyrase and topoisomerase IV. Each class of antibiotics offers unique advantages and is used to target specific types of bacterial infections, allowing for more tailored and effective treatments.

What Challenges Are Associated with Antibiotic Resistance?

Antibiotic resistance is one of the most significant challenges facing modern medicine. Overuse and misuse of antibiotics in human medicine and agriculture have accelerated the development of resistant bacterial strains. When bacteria are exposed to antibiotics, they can evolve mechanisms to survive, such as producing enzymes that deactivate the drug, altering the drug’s target site, or pumping the drug out of the cell. Resistant infections are harder to treat, often requiring more potent antibiotics, longer treatment durations, and in some cases, leading to increased mortality. The spread of multidrug-resistant organisms, such as methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE), underscores the urgency of this issue. Efforts to combat antibiotic resistance include the development of new antibiotics, the implementation of antibiotic stewardship programs to optimize the use of existing antibiotics, and global initiatives to reduce antibiotic misuse and promote research into alternative therapies.

What Factors Are Driving the Growth in the Antibiotics Market?

The growth in the antibiotics market is driven by several factors. Increasing prevalence of bacterial infections, particularly in developing regions with high population densities and limited access to healthcare, is a significant driver. Advances in diagnostic technologies are improving the detection and identification of bacterial pathogens, leading to more targeted antibiotic therapies. The rise of hospital-acquired infections, which are often resistant to multiple antibiotics, necessitates the development and use of newer, more effective treatments. Additionally, ongoing research and development efforts are focused on discovering novel antibiotics with unique mechanisms of action to overcome existing resistance issues. Regulatory support and funding from governments and health organizations are also bolstering the antibiotics market by facilitating the research, approval, and commercialization of new antibiotic agents. Furthermore, the expansion of healthcare infrastructure and increased healthcare spending in emerging economies are contributing to greater access to and demand for antibiotics, thereby driving market growth.

SCOPE OF STUDY:

The report analyzes the Antibiotics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline, Other Drug Classes); Route of Administration (Parenteral, Oral, Other Routes of Administration)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 209 Featured) -

  • Abbott Laboratories, Inc.
  • Allergan PLC
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi
  • Shionogi, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Antibiotics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Bacterial Infections Throws the Spotlight on Antibiotics
    • Advances in Antibiotic Drug Discovery and Development Spurs Growth in Antibiotics Market
    • Increasing Use in Livestock and Agriculture Expands Addressable Market Opportunity
    • Growing Threat of Antibiotic Resistance Strengthens Business Case for Novel Antibiotics
    • Regulatory Approvals for New Antibiotic Classes Generates Demand for Advanced Therapeutics
    • Technological Innovations in Antibiotic Formulation Drives Adoption of Improved Treatments
    • Expansion of Antibiotic Stewardship Programs Sustains Growth in Antibiotics Market
    • Rising Demand for Antibiotics in Emerging Economies Accelerates Market Demand
    • Development of Narrow-Spectrum Antibiotics Spurs Innovation in Targeted Therapy
    • Increasing Investment in Antibiotic Research and Development Propels Market Growth
    • Growing Awareness of Infection Control Measures Strengthens Market Potential for Antibiotics
    • Development of Combination Therapies to Combat Resistance Generates Interest in Antibiotics
    • Increasing Focus on Pediatric and Geriatric Antibiotic Treatments Drives Adoption
    • Expansion of Applications in Healthcare-Associated Infections Spurs Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antibiotics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Penicillin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Penicillin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Penicillin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Cephalosporin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Macrolides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Macrolides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Fluoroquinolones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Fluoroquinolones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Fluoroquinolones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Tetracycline by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Routes of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • JAPAN
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • CHINA
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • EUROPE
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • FRANCE
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • GERMANY
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Antibiotics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • INDIA
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Antibiotics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Antibiotics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • AFRICA
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제